Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial
Kantarjian H et al. Leukemia, July 2026 (epub ahead of print) – open access publication
Link to full abstract